# Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

> **NCT04583007** · — · NO_LONGER_AVAILABLE · sponsor: **Shire**

## Conditions studied

- Hereditary Angioedema (HAE)
- Angioedema

## Interventions

- **DRUG:** Lanadelumab 150 mg
- **DRUG:** Lanadelumab 300 mg

## Key facts

- **NCT ID:** NCT04583007
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2023-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04583007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04583007, "Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04583007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*